RepliCel Life Sciences Media de recomendación
¿Qué es el Media de recomendación de RepliCel Life Sciences?
El Media de recomendación de RepliCel Life Sciences, Inc. es 2.00
¿Cuál es la definición de Media de recomendación?
La media de recomendación es la media de las calificaciones de los analistas de las acciones que van desde 1.0 (compra fuerte) a 5.0 (venta fuerte).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Media de recomendación de compañías en Sector Health Care en TSXV en comparadas con RepliCel Life Sciences
¿Qué hace RepliCel Life Sciences?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Empresas con media de recomendación similar a RepliCel Life Sciences
- Cabot Oil & Gas tiene Media de recomendación de 1.96
- Truist tiene Media de recomendación de 1.96
- Delta Air Lines tiene Media de recomendación de 1.96
- Discover Services tiene Media de recomendación de 1.96
- United Micro Electronics tiene Media de recomendación de 1.96
- Tapestry Inc tiene Media de recomendación de 1.97
- RepliCel Life Sciences tiene Media de recomendación de 2.00
- Trip.com Ltd tiene Media de recomendación de 2.03
- Sherwin-Williams Co tiene Media de recomendación de 2.03
- Canadian Pacific Kansas City tiene Media de recomendación de 2.03
- Arista Networks Inc tiene Media de recomendación de 2.03
- Anheuser-Busch InBev SA/NV tiene Media de recomendación de 2.03
- Celanese Corp tiene Media de recomendación de 2.04